BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
21/08/26	€0.002000	0.00%
20/08/26	€0.002000	0.00%
19/08/26	€0.002000	0.00%
18/08/26	€0.002000	0.00%
17/08/26	€0.002000	0.00%

Real-time Euronext Bruxelles

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles 19:55:00 21/08/2026 +04			5-day change	1st Jan Change
0.002000 ^EUR	0.00%		0.00%	-13.04%

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.75M 1.4M 1.29M 2.41M 168M 2.45M 16.6M 6.47M 84.25M 6.58M 6.44M 279M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 33.67M 26.98M 24.7M 46.35M 3.22B 46.97M 319M 124M 1.62B 126M 124M 5.35B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
13/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
29/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
05/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
01/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

BioSenic SA Stock

Stocks

BIOS

BE0974280126

Pharmaceuticals

Valuation: BioSenic SA

Chart: BioSenic SA

Latest news : BioSenic SA

Analysts' recommendations: BioSenic SA

Press Releases: BioSenic SA

News in other languages: BioSenic SA

Quotes and Performance

Course Extremes

Managers and Directors: BioSenic SA

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0.19
5 years	0		0.35
10 years	0		0.35

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSENIC SA	0.00%	0.00%	-20.00%	-95.24%	1.52M
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.86%	+128.23%	1,119B
JOHNSON & JOHNSON	+1.07%	+3.80%	+51.03%	+61.48%	651B
ABBVIE INC.	+1.20%	+6.21%	+26.47%	+76.45%	468B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.09%	+47.70%	374B
NOVARTIS AG	+0.85%	+4.07%	+23.88%	+41.58%	302B
ASTRAZENECA PLC	+1.26%	+6.81%	+1.59%	+14.67%	259B
AMGEN INC.	+1.88%	+5.81%	+48.54%	+68.52%	238B
NOVO NORDISK A/S	+1.59%	+2.09%	-15.52%	-52.29%	208B
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+25.81%	+92.42%	181B
Average	+1.16%	+4.48%	+26.18%	+38.35%	379.99B
Weighted average by Cap.	+1.14%	+5.09%	+44.31%	+72.55%

	2023	2024
Net sales	336K 392K 314K 288K 540K 37.53M 547K 3.71M 1.45M 18.85M 1.47M 1.44M 62.36M	102K 119K 95.44K 87.36K 164K 11.39M 166K 1.13M 440K 5.72M 447K 437K 18.93M
Net income	-28.78M -33.6M -26.93M -24.65M -46.26M -3.21B -46.87M -318M -124M -1.61B -126M -123M -5.34B	-4.77M -5.57M -4.46M -4.08M -7.66M -533M -7.77M -52.71M -20.55M -268M -20.9M -20.45M -885M
Net Debt	28.04M 32.74M 26.24M 24.02M 45.07M 3.13B 45.67M 310M 121M 1.57B 123M 120M 5.2B	27.34M 31.91M 25.58M 23.41M 43.94M 3.05B 44.52M 302M 118M 1.53B 120M 117M 5.07B

3 months	-9.09%
6 months	-16.67%
Current year	-13.04%